Specialty and Rare Pipeline Digest - Q3 2026
As the pipeline of new specialty pharmaceuticals continues to evolve, it becomes even more crucial to stay abreast of recent and emerging therapeutic options on the horizon.
Our quarterly publication provides all industry stakeholders with important insights into:
- Specialty, rare disease, and cell and gene therapy pipelines
- Recent approvals
- Upcoming FDA reviews
Get a Copy of This Pipeline Digest
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.